Pfizer bureau in Sanford to assistance have new vaccine

A new version of the Prevnar childhood vaccine that sovereign regulators authorized Wednesday is approaching to be a big seller for Pfizer and will be partly constructed at the companys drug bureau in Sanford.

Pfizer acquired the plant, that employs about 1,000 people, when it paid for Wyeth in October. The trickery creates the stream version of Prevnar and will be concerned in dual stairs of producing Prevnar 13. Other stairs will be rubbed at opposite Pfizer sites, pronounced orator Rick Chambers.

"At this time, there is no plan for becoming different staff formed on todays announcement," Chambers wrote in an email.

But one some-more work from prolongation of the new vaccine doesnt finish doubt for employees at the Sanford plant. Pfizer is still reviewing the production operations as it seeks some-more ways to cut costs following the Wyeth takeover. The association plans to yield an refurbish on that examination as shortly as subsequent month.

"At this point there are no decisions done on any of the plants in the tellurian network," Chambers wrote.

Last fall, Pfizer cut about 170 researchers in Sanford and Morrisville as piece of a incomparable streamlining of the investigate operations.

The Food and Drug Administration authorized Prevnar thirteen for impediment of one some-more strains of illnesses such as pneumonia and meningitis. Its the initial new Pfizer product to win FDA capitulation given the Wyeth purchase.

Analysts design the vaccine to in the future beget some-more than $5 billion a year in revenue, and turn Pfizers greatest product. The association paid for Wyeth to assistance equivalent negligence sales of alternative blockbuster drugs, together with Lipitor, the cholesterol disinfectant that loses obvious insurance subsequent year.

The comparison version of Prevnar generated $2.72 billion in sales during 2008, the ultimate total available. Pfizer has pronounced it will lift the comparison version off the marketplace as Prevnar thirteen is authorized and introduced worldwide, Bloomberg News reported.

GlaxoSmithKline creates a opposition vaccine called Synflorix, but it isnt authorized in the U.S.